$1.97
11.93% today
Nasdaq, Sep 11, 10:17 pm CET
ISIN
US45782T1051
Symbol
INMB

Inmune Bio, Inc. Stock price

$1.97
-0.43 17.92% 1M
-6.20 75.89% 6M
-2.70 57.82% YTD
-4.26 68.38% 1Y
-6.42 76.52% 3Y
-7.87 79.98% 5Y
-6.02 75.34% 10Y
-6.02 75.34% 20Y
Nasdaq, Closing price Thu, Sep 11 2025
+0.21 11.93%
ISIN
US45782T1051
Symbol
INMB
Industry

Key metrics

Basic
Market capitalization
$46.8m
Enterprise Value
$13.4m
Net debt
positive
Cash
$33.4m
Shares outstanding
26.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
935.8 | 1,376.3
EV/Sales
268.4 | 394.7
EV/FCF
negative
P/B
1.6
Financial Health
Equity Ratio
81.1%
Return on Equity
-131.1%
ROCE
-135.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$50.0k | $34.0k
EBITDA
- | -
EBIT
$-39.4m | $-48.9m
Net Income
$-55.4m | $-39.8m
Free Cash Flow
$-33.3m
Growth (TTM | estimate)
Revenue
-37.5% | 240.0%
EBITDA
- | -
EBIT
-4.3% | -14.8%
Net Income
-46.8% | 5.4%
Free Cash Flow
-46.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-78,858.0%
Net
-110,830.0% | -117,074.2%
Free Cash Flow
-66,532.0%
More
EPS
$-2.4
FCF per Share
$-1.3
Short interest
24.2%
Employees
18
Rev per Employee
$0.0
Show more

Is Inmune Bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Inmune Bio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Inmune Bio, Inc. forecast:

8x Buy
67%
4x Hold
33%

Analyst Opinions

12 Analysts have issued a Inmune Bio, Inc. forecast:

Buy
67%
Hold
33%

Financial data from Inmune Bio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.05 0.05
38% 38%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 8.90 8.90
12% 12%
17,800%
- Research and Development Expense 31 31
11% 11%
61,720%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -39 -39
4% 4%
-78,858%
Net Profit -55 -55
47% 47%
-110,840%

In millions USD.

Don't miss a Thing! We will send you all news about Inmune Bio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inmune Bio, Inc. Stock News

Neutral
Seeking Alpha
about one month ago
INmune Bio, Inc. (NASDAQ:INMB ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Christopher Barnum - Corporate Participant Daniel Carlson - Corporate Participant David J. Moss - CFO, Treasurer & Secretary Mark William Lowdell - Chief Scientific Officer & Chief Manufacturing Officer Raymond Joseph Tesi - Co-Founder, President, CEO, Chief Medical Officer & Chairman...
Neutral
The Motley Fool
about one month ago
INmune Bio (INMB) Q2 Loss Widens 110%
Neutral
GlobeNewsWire
about one month ago
BOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial (the “CaRe PC” trial) of INKmune™ for men with metastatic castration-resistant prostate cancer (mCRPC) has met its primary and secondary endpoints and is now closed to further enrollment.
More Inmune Bio, Inc. News

Company Profile

INmune Bio, Inc. focuses on controlling components of the immune system to activate an immune response against cancer and Alzheimer's disease. Its product pipeline INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer, and LIVNATE. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.

Head office United States
CEO Raymond Tesi
Employees 18
Founded 2015
Website www.inmunebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today